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OBJECTIVES: Fifteen committees currently undertake drug evaluations at the re-
gional level in Spain that serve as the basis for pharmaceutical policy decisions
within primary care or specialized care above single hospitals. The objective of this
study was to examine the quality of the assessment procedures under which drug
evaluations are undertaken by these regional committees. METHODS: We ana-
lyzed the quality of the assessment procedures on the basis of 4 criteria: whether
operating procedures (OP) are public, whether there is dialog with the marketing
authorization holder (MAH) during the assessment, whether drug assessments are
public, whether a full economic evaluation (EE) (i.e. costs and health outcomes are
taken into account) is undertaken. We reviewed all the public information regard-
ing OPs and drug assessments undertook by these committees. Search was con-
ducted in Google, official bulletins and official Regional Health Systems websites,
with no limits. RESULTS: In primary care, 2 out of 8 committees follow a public OP
when assessing a new drug and explicitly have interaction with the MAH during
the assessment. All the committees publish their assessments but none of them
undertake full EEs (e.g. only drug costs are considered). Within specialized care 3
out of 7 committees follow a public OP, 2 of which interact with the MAH. 3 com-
mittees publish their assessments and also 3 undertake full EEs. Overall 33% of
committees follow a public OP, 27% have interaction with the MAH during the
assessment, 73% publish their assessments and 20% undertake a full EE.
CONCLUSIONS: There is room for improvement in the work undertaken by re-
gional drug evaluation committees regarding transparency of OPs, dialog with the
MAH and use of EE as a tool for informing decision making.
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OBJECTIVES: This study seeks to evaluate the impact on market access for phar-
maceuticals in the UK following the introduction of Value Based Pricing (VBP).
METHODS: SMC advice and final NICE guidance issued between 1 June 2010 and 31
May 2011 were assessed to determine the number and outcome of total appraisals,
of Single Technology Appraisals (STAs), and of appraisals based on a manufacturer
submission. The current duration of a NICE STA review and the time required to
provide guidance under the NICE Scientific Advice Programme were also reviewed.
RESULTS: Under VBP, all new originator drugs entering the market and all new
indications of existing medicines will be reviewed: as is the case currently in Scot-
land. Over the 12-month period, the SMC reviewed a total of 101 new drugs or
indications, of which 18 were resubmissions, so a total of 83 original reviews were
performed. NICE – which only reviews treatments it is commissioned to review by
the DH – conducted 28 STAs. Some 47% of SMC drug reviews resulted in positive
guidance – rising to 58% among reviews based on a manufacturer submission. The
average length of a NICE technology appraisal is 18 months; however, NICE scien-
tific guidance can be provided in as little as 15 weeks. CONCLUSIONS: Pharmaceu-
tical market access in England and Wales will potentially improve following the
introduction of VBP as more products are reviewed in a more timely manner. Three
times more originator medicines or new indications will be reviewed in compari-
son to the number currently reviewed by NICE. The average duration of an ap-
praisal under VBP could to be just 15 weeks – 19.2% of the time currently required.
On the negative side, manufacturers would be expected to offer products at an
acceptable price – calculated in accordance with yet-to-be-finalised criteria – in
exchange for gaining reimbursement.
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OBJECTIVES: Many countries have to face policy dilemma between cost contain-
ment policy and industry policy which may encourage pharmaceutical firms in
terms of R&D. This study is trying to investigate the following issues: firstly, it tries
to figure out the major determinants of R&D investment of pharmaceutical firms.
Secondly, it compares the effects of those determinants on R&D intensity between
U.S. and the rest of the world. METHODS: Using a 10 year panel dataset extracted
from several sources such as Compustat, KISINFO, PhRMA, and JPMA, this study
empirically investigates whether US pharmaceutical market which is relatively
unregulated has higher profitability and cash flows than its counterparts where
drug prices are regulated by government agencies. Employing OLS, random-effects,
and fixed-effects specifications for established R&D investment models from the
literature, the study tries to explore the links between pharmaceutical price regu-
lation and firm R&D investment intensity. RESULTS: Data from 32 major pharma-
ceutical firms have been collected for the years 2000 through 2009, and several
models of the determinants of R&D investment were estimated. The regression
results show that expected profits and lagged cash flows are principal determi-
nants of firm R&D-to-sales ratios. It has been argued that pharmaceutical price
regulation influences R&D investment through both of these channels, resulting in
an expected-profit effect and a cash-flow effect. The former influences R&D con-
temporaneously while the latter effect operates with at least 1 year lag. From a
comparison of effects on R&D intensity, U.S. has about 4 or 5 times higher profit-
ability effect than non-U.S. where pharmaceutical price regulation is so strictly
implemented. CONCLUSIONS: A slower R&D growth as a consequence of price
regulation may be politically acceptable because current consumer can benefit, but
we can predict that the cost to the future generations is substantial.
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OBJECTIVES: To know the perception of undergraduate students about various
aspects (Cost, quality and safety) of over-the-counter and prescription medicines.
METHODS: Structured, non-disguised, pretested self-administered questionnaire
was used for the study. The total sample was 200 undergraduates (Group 1 – 100
science graduates and Group 2 – 100 arts graduates). ‘t’ Test was used to analyze the
data. RESULTS: Most of the science graduates (78%) have expressed the cost of
medicines were affordable and feel appropriate. They expressed Research and
Development and manufacturing requires huge money and time, hence the cost.
On the quality front, most of the respondents (68%) were satisfied. However, as far
as safety is concerned, many respondents (79%) have expressed that they are safe
as they pass through several phases of clinical trials. They were in an opinion that
over-the-counter medicines are safer than the prescription medicines. Whereas
most of the arts graduates (84%) have said that cost of medicines are higher and
were not having any idea about the research, development and manufacturing
costs involved. Many respondents (87%) said that quality is just acceptable. Quite a
few respondents (69%) said that medicines are not safe and have to be taken with
caution, whether it is over-the-counter or prescription medicines. CONCLUSIONS:
Significant differences were noted between two groups of respondents. Sciences
graduates feel the cost charged on medicines is appropriate, are of right quality and
often safe. Whereas arts graduates were affirmative to quality and safety aspect
but were in opinion that costs charged on medicines are higher.
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OBJECTIVES: It has been reported that 50-65 % of the Indian population has no
access to essential medicines, whereas a small portion of the population using
medicines, do so irrationally and unnecessarily. Irrational use of medicines leads to
wastage of national wealth and also emerging Adverse Drug Reactions (ADRs) and
developing resistance to some drugs especially antibiotics. In order to improve the
situation, several interventions have been suggested. One such intervention is
promoting the concept of Rational Use of Medicines (RUM) through conducting
workshops and seminars involving all stake holders in the health care system. This
study was conducted to determine the effect of an intervention on drug use pattern
in a community.METHODS: Study was conducted in the semi urban areas covering
three districts of West Bengal, India. Community pharmacies mainly serving the
prescriptions of private practioners were involved in this study. Prescriptions were
collected from community pharmacies, serving prescriptions of private practitio-
ners in a semi urban area within a month. 30 prescriptions each from 10 pharma-
cies were collected from the area where workshop/seminars were conducted dur-
ing the last two years. 30 prescriptions each from 10 pharmacies were collected
where no such workshop/seminars were organized for the past two years.
RESULTS: Results show that the average number of medicines prescribed per en-
counter reduced from 2.84 to 2.18. % of prescriptions for generics improved signif-
icantly from nil to 22.78. % of prescriptions for antibiotics and vitamin tonics re-
duced significantly, i.e. from 54.33 to 34.66 and from 16 to 12 respectively, % of
prescriptions for injections reduced from 3.66 to 0.33 .Average number of FDCs
reduced from 1.13 to 0.55. CONCLUSIONS: It reveals from the result mentioned
above that medicine use indicators have improved significantly by intervention i.e.
disseminating information on rational use of medicines amongst the stake holders
of a health care system.
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OBJECTIVES: To identify differences in drug consumption in two neighbouring
countires, B&H with decentralized HC system and Croatia with centralized HC
system.METHODS: In this research we have studied 12 reimbursement lists in B&H
and 1 in Croatia. In 2009, in B&H, the total drug consumption was 467 mBAM, or
37.6% of drug consumption in the same year in Croatia (43.6% if adjusted for num-
ber of inhabitants, and 37.9% if adjusted for VAT and number of inhabitants). All
drugs were included in the analysis irrespectively of the co-payment and prescrip-
tion status (retail or hospital) and were grouped based on ATC level 3 and INN. Top
ten ATC 3 groups with highest expenditure in 2009 were identified and cross ref-
erenced with top ten in HR. For these groups BH spent 45% of its combined medi-
cine budget and HR spent 37%. RESULTS: The most significant differences in the
share of relevant ATC 3 group in the total drug expenditure were observed for
antihypertensive drugs: C09B (5,9% BH; 3,0% HR), C09A (4,6% BH; 2,5% HR), anxiolyt-
ics: N05B (3,4% BH; 1,0% HR) and beta-lactam antibiotics: J01C (3,2% BH; 1,5% HR).
High share of drug expenses related to C09B and C09A groups can be explained by
very high cardiovascular mortality rate, causing 2,5 time more deaths each year
than malignant diseases. In BH we also observed very low consumption share of
statins C10A (2,0% BH; 4,5% HR) and antipsychotics N05A (1,8% BH; 3,7% HR). In
spite of restrictive policies regulating availability of oncology medicines to pa-
tients, we did not observe significant difference in L01X (4,3% BH; 5,2% HR).
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CONCLUSIONS: Cardiovascular diseases are still leading cause of death in BH, so
we suggest deeper analysis of all guidelines, programs and interventions focused to
decreasing CV mortality and making Government(s) expenditure in CV drugs more
efficient.
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OBJECTIVES: In October 2010, the Irish healthcare payer (i.e. the Health Service
Executive, HSE) introduced a €0.50c charge on all prescription items dispensed
under the General Medical Services (GMS) scheme, the largest of the community
drug schemes in Ireland covering approximately 40% of the population. We inves-
tigated whether this charge was associated with changes in drug utilisation.
METHODS:Monthly prescription dispensing was analysed from September 2009 to
September 2010 (pre-intervention period) and then from November 2010 to March
2011 (post intervention period). In addition to utilization (prescription items) and
cost information the database classifies drugs according to whether they are ge-
neric, off-patent or patent. The volume of drugs dispensed in each class was cal-
culated and trends in utilsation and expenditure from the pre intervention period
were compared with those in the post intervention period using segmented regres-
sion analysis. All analyses were performed using SAS (v9.1, SAS Institute Inc. Cary,
US). Statistical significance at p0.05 is assumed throughout. RESULTS: No effect
was noted following the introduction of the prescription charge on prescription
items in the post intervention period. A decrease in ingredient cost was noted
however, for generics in the month post the intervention (p0.01). A change in the
overall trend for ingredient cost of off-patents was noted also in the post interven-
tion period (p0.05). The intervention had no significant effect on utilization and
expenditure of patented medicines. CONCLUSIONS: The study findings suggest
that the recent introduction of a prescription charge has had no significant effect
on utilization of prescription medicines, while decreased expenditures could be
attributed to changes in the pricing mechanisms for generics and off-patents oc-
curring around this time. Further analysis is warranted to determine if the effect on
utilization is sustained over time.
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INAPPROPRIATE PRESCRIPTIONS BASED ON BEERS CRITERIA IN ELDERLY
PATIENTS TREATED AT HOME
Imai H1, Nakao H2, Sata F2
1National Institute of Public Health, Wako-shi, Saitama-ken, Japan, 2National Institute of Public
Health, Wako-shi, Japan
OBJECTIVES: Various studies have been performed on potentially inappropriate
medications (PIM) in the elderly. In developed countries, Beers criteria or Zhan
criteria are widely utilized. We developed a Japanese version of Beers criteria and
are using it in clinical practice. Almost no epidemiological surveys have been per-
formed on PIM in Japan. However, it is clear that dangerous prescriptions including
unnecessary and multidrug prescriptions are often written. The objective of this
study is to clarify the prevalence of PIM in elderly people 65 or older treated at
home. METHODS: The subjects were elderly people 65 or older under home care in
the Tokyo area who were prescribed drugs in routine practice. The survey was
conducted in 300 randomly sampled pharmacies. The survey forms were distrib-
uted to the pharmacists by mail. After the pharmacists entered the drug prescrip-
tion information, they returned the forms by post. RESULTS: Replies were obtained
from 130 pharmacies (recovery rate: 43.3%). The 84 patients included 30 men and 54
women with a mean age of 82. Medical conditions included hypertension (56%),
cognitive impairment (21.4%), ischemic heart disease (16.7%) and diabetes (11.9%).
Drugs prescribed based on the Japanese version of Beers criteria accounted for
52.4% and included famotidine (30%), digoxin (5%) and ticlopidine (3.3%). Drug
types included peptic ulcer drugs (48.3%), vasodilators (8.3%) and anti-Parkinson-
ism agents (6.7%). CONCLUSIONS: In the first epidemiological survey on PIM in the
elderly undergoing home care in Japan, PIM were evident in 52.4%, a high percent-
age compared data on PIM to date. Peptic ulcer drugs were the most common and
prescriptions of ticlopidine were also high when compared with other countries.
This survey had several limitations such as being limited to Tokyo and relatively
few subjects. In the future, we hope to perform a survey with greater precision in
more subjects in the future.
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BACKGROUND: The Valencian Community, with 5,000,000 inhabitants, is imple-
menting a system of pharmaceutical management to reduce costs. This system is
based on classifying patients in groups using the case mix system, Clinical Risk
Groups. An electronic tool has been developed based on www to manage patients
with chronic conditions and monitor pharmaceutical expenditure in primary
health care. GPs receive a report on the real pharmaceutical cost that is being
incurred and the optimum cost adjusted by CRG. OBJECTIVES: To evaluate the
predictive ability of the Clinical Risk Group System in predicting pharmaceutical
expenditure in the Valencian Community. METHODS: We ran a generalized linear
model to examine the predictive validity of the CRG system and report the corre-
lation between the predicted and observed expenditures. We reported mean pre-
dictive ratios across medical condition and cost-defined groups.RESULTS:The CRG
system predicted pharmaceutical expenditure with precision, excepting for groups
8 and 9 of ACRG3. A new weight adjusted model has been developed to better fit
pharmaceutical expenditure in primary health care to the real situation in
Valencia. CONCLUSIONS: In order to use the CRG system to estimate pharmaceu-
tical expenditure in primary health care, the groups of greater clinical risk must be
weight adjusted, as the pharmaceutical consumption of these groups is hospital-
based.
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OBJECTIVES: The principle of equitable treatment establishes that everyone has
the right of access to preventive health care and the right to benefit from medical
treatment. Variations in market uptake of orphan drugs have important implica-
tions with respect to access to care and inequality of treatment. Therefore, the aim
of this descriptive study is to examine the uptake of orphan drugs in Europe.
METHODS:We analyzed both the sales and volume uptake from 17 orphan drugs in
24 European countries from 2001 until the beginning of 2010 using the IMS Health
database. Countries were clustered based on differences in demographics, gross
domestic product (GDP) and patent protection law. RESULTS: This study shows
that there is a difference in the uptake of orphan drugs across European countries.
Not only does the number of orphan drugs launched differ, the sales on orphan
drugs and the share of orphan drugs sales on total market sales also vary strongly.
Additionally, the volume uptake and the share spent on orphan drugs during the
first year after the launch are highest in countries with high GDP and strong patent
laws. CONCLUSIONS: The uptake of orphan drugs could be promoted through a
variety of mechanisms such as the harmonization of European patent laws, the
implementation of conditional reimbursement mechanisms, and the introduction
of non-binding EU scientific assessment reports on the clinical added value of
orphan drugs.
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OBJECTIVES: Most countries including Malaysia are facing escalating healthcare
expenditures. The purpose of this study was to evaluate general public’s expendi-
ture on health products. METHODS: A cross-sectional study using convenience
sampling technique was used in this study. 800 questionnaires were distributed to
the general public in the state of Penang Malaysia. All data were analysed using
descriptive and appropriate inferential statistics at alpha value of 0.05. RESULTS:A
total of 56.73% of total 704 respondents felt that branded medicines were expensive
or moderate, while 56.53% of them felt that the cost of generic medicines were
moderate. In terms of private market, the costs of health products sold in commu-
nity pharmacies were perceived to be cheaper as compared to private clinics and
private hospitals. The mean of monthly expenditure per household on moderns
medicines, vitamins and non-herbal health supplements, and herbal products
were RM 171.80, RM 125.41 and RM 61.03, respectively (1 USD  RM3.30). Respon-
dents’ age, gender, race and income were found significantly affecting on patients’
responses.CONCLUSIONS:This study has highlighted the need to control the med-
icines prices in the private market especially in private clinics and private hospi-
tals. There is a need to promote generic products and to educate patients about the
evidence based medicine since a good proportion of their income is monthly spent
on herbal products.
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OBJECTIVES:To assess the impact of pharmaceutical part of the health care reform
in Croatia as compared with trends observed in EU countries. METHODS: Detailed
historical pharmaceutical expenditure was analysed using MIDAS, an IMS Health
proprietary database, as well as a variety of other published secondary data
sources. Croatian trends have been compared with those of a number of bench-
mark countries, categorised either as Peer Countries (Slovakia, Czech, Hungary)
and Aspirational Countries known to have systems that have been ensuring excel-
lent health care outcomes (France, The Netherlands, Austria). RESULTS: Although
total health expenditure in Croatia, as percentage of GDP is at EU level (7.8%), total
pharmaceutical spend per capita is very low, 128€, with more than 80% coming
from public funding. Pharmaceutical expenditure is not driving the overall health
cost growth; in fact, pharmaceutical spend as a % of total health expenditure has
been declining since 2003. The complex set of cost containment measures, includ-
ing limitation of GP’s prescriptions, imposed by Croatian Health Insurance Institute
is the likely cause of this trend. The most relevant finding of this study is that
Croatia has been historically very low in drug use in terms of ‘volume per capita’
compared to benchmark countries. In 2010 Croatian patients consumed approx.
20-25% less prescription medicines per capita than the average of peer and aspira-
tional countries. CONCLUSIONS: If the observed trends are allowed to continue, it
will be difficult for Croatia to keep pace with its peers in providing adequate phar-
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